Citadel Advisors’s BioLineRX BLRX Stock Holding History

Citadel Advisors’s Portfolio BLRX Stock Details BLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12,000	Closed	-$34.2K	–	13014
2025 Q4	$34.2K	Buy	+12,000	New	+$41.5K	﹤0.01%	12183
2025 Q3	–	Sell	-12,200	Closed	-$55.8K	–	12787
2025 Q2	$55.8K	Buy	+12,200	New	+$45.1K	﹤0.01%	11719
2025 Q1	–	Sell	-128	Closed	-$1.08K	–	14506
2024 Q4	$1.08K	Sell	128 -30	-19%	-$443	﹤0.01%	14226
2024 Q3	$3.38K	Sell	158 -122	-44%	-$3.35K	﹤0.01%	13661
2024 Q2	$6.34K	Sell	280 -25	-8%	-$671	﹤0.01%	13338
2024 Q1	$13.7K	Buy	305 +195	+177%	+$9.78K	﹤0.01%	13286
2023 Q4	$6.91K	Buy	110 +5	+5%	+$309	﹤0.01%	13326
2023 Q3	$7.64K	Buy	105 +102	+3,400%	+$6.85K	﹤0.01%	13247
2023 Q2	$160	Buy	+3	New	+$166	﹤0.01%	14203
2022 Q1	–	Sell	-593	Closed	-$48K	–	13595
2021 Q4	$48K	Sell	593 -1,472	-71%	-$153K	﹤0.01%	13267
2021 Q3	$226K	Buy	2,065 +1,255	+155%	+$149K	﹤0.01%	11707
2021 Q2	$91K	Buy	+810	New	+$95.2K	﹤0.01%	12988

Other funds holding BLRX

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

BCV

Banque Cantonale Vaudoise Lausanne, Switzerland $722M AUM 30.45% 1-Year Est. Return

NRG

Nemes Rush Group Novi, Michigan $1.21B AUM 33.22% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Citadel Advisors's BLRX Position: Q2 2026 in Review

Citadel Advisors opened a new position in BioLineRX (BLRX) in Q2 2026: 14,796 shares worth $45.9K. The stake represents ﹤0.01% of the portfolio and ranks #13156 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in BLRX as recently as Q4 2025.

Citadel Advisors first reported a position in BLRX in Q1 2014 and has held it in 21 quarters since. The position peaked at $451K in Q3 2021. 14 funds tracked by Wall St. Rank hold BLRX as of Q2 2026.

Citadel Advisors held 14,796 shares of BioLineRX worth $45.9K as of Q2 2026.
BioLineRX was a new Citadel Advisors position in Q2 2026.
BioLineRX made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13156 holding.
Citadel Advisors first reported a position in BioLineRX in Q1 2014 and has held it in 21 quarters since.
Citadel Advisors's BioLineRX position peaked at $451K in Q3 2021.
14 funds tracked by Wall St. Rank held BioLineRX as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.